BeOne Medicines Shares Open Nearly 4% Higher as Company Unveils Clinical Data for Multiple Solid Tumour Programs with Clear Future Development Plans

Stock News09:32

BeOne Medicines (06160) opened nearly 4% higher. As of press time, the stock was up 3.73%, trading at HK$228.2, with a turnover of HK$36.279 million.

On the news front, BeOne Medicines announced key progress across multiple solid tumour pipeline programs at the 2026 ESMO Congress: its GPC3/4-1BB bispecific antibody for advanced liver cancer achieved an ORR of 36% in Phase I trials with an excellent safety profile; its PRMT5 inhibitor demonstrated an ORR of 38.5% in EGFR wild-type lung cancer, with an intracranial response rate of 30.8%; and its CEA ADC achieved an ORR of as high as 56% in patients with high CEA expression in lung cancer.

The company plans to initiate a global registrational clinical trial for later-line liver cancer before the end of 2026, while the PRMT5 inhibitor and CEA ADC are expected to advance to later-stage development in 2027.

CICC released a research report stating that BeOne Medicines has made the latest progress in its solid tumour pipeline. The firm maintained its 2026 and 2027 earnings forecasts unchanged and kept its "Outperform Industry" rating. Based on a DCF model, the firm maintained its target prices for A-shares, H-shares, and US-listed shares at RMB 340, HK$266, and US$445, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121491466?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-29 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121491466","market":"other","top_or_hot":-1,"title":"BeOne Medicines Shares Open Nearly 4% Higher as Company Unveils Clinical Data for Multiple Solid Tumour Programs with Clear Future Development Plans","media":"Stock News","content":"<p>BeOne Medicines (<b>06160</b>) opened nearly 4% higher. As of press time, the stock was up 3.73%, trading at HK$228.2, with a turnover of HK$36.279 million.<br><br>On the news front, <b>BeOne Medicines</b> announced key progress across multiple solid tumour pipeline programs at the 2026 ESMO Congress: its GPC3/4-1BB bispecific antibody for advanced liver cancer achieved an ORR of 36% in Phase I trials with an excellent safety profile; its PRMT5 inhibitor demonstrated an ORR of 38.5% in EGFR wild-type lung cancer, with an intracranial response rate of 30.8%; and its CEA ADC achieved an ORR of as high as 56% in patients with high CEA expression in lung cancer.<br><br>The company plans to initiate a global registrational clinical trial for later-line liver cancer before the end of 2026, while the PRMT5 inhibitor and CEA ADC are expected to advance to later-stage development in 2027.<br><br><b>CICC</b> released a research report stating that <b>BeOne Medicines</b> has made the latest progress in its solid tumour pipeline. The firm maintained its 2026 and 2027 earnings forecasts unchanged and kept its \"Outperform Industry\" rating. Based on a DCF model, the firm maintained its target prices for A-shares, H-shares, and US-listed shares at RMB 340, HK$266, and US$445, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Shares Open Nearly 4% Higher as Company Unveils Clinical Data for Multiple Solid Tumour Programs with Clear Future Development Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Shares Open Nearly 4% Higher as Company Unveils Clinical Data for Multiple Solid Tumour Programs with Clear Future Development Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-29 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines (<b>06160</b>) opened nearly 4% higher. As of press time, the stock was up 3.73%, trading at HK$228.2, with a turnover of HK$36.279 million.<br><br>On the news front, <b>BeOne Medicines</b> announced key progress across multiple solid tumour pipeline programs at the 2026 ESMO Congress: its GPC3/4-1BB bispecific antibody for advanced liver cancer achieved an ORR of 36% in Phase I trials with an excellent safety profile; its PRMT5 inhibitor demonstrated an ORR of 38.5% in EGFR wild-type lung cancer, with an intracranial response rate of 30.8%; and its CEA ADC achieved an ORR of as high as 56% in patients with high CEA expression in lung cancer.<br><br>The company plans to initiate a global registrational clinical trial for later-line liver cancer before the end of 2026, while the PRMT5 inhibitor and CEA ADC are expected to advance to later-stage development in 2027.<br><br><b>CICC</b> released a research report stating that <b>BeOne Medicines</b> has made the latest progress in its solid tumour pipeline. The firm maintained its 2026 and 2027 earnings forecasts unchanged and kept its \"Outperform Industry\" rating. Based on a DCF model, the firm maintained its target prices for A-shares, H-shares, and US-listed shares at RMB 340, HK$266, and US$445, respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"","article_id":"1121491466","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121491466","pubTimestamp":1793237561,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BeOne Medicines (06160) opened nearly 4% higher. As of press time, the stock was up 3.73%, trading at HK$228.2, with a turnover of HK$36.279 million.On the news front, BeOne Medicines announced key...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","VXUS":"国际股票ETF-Vanguard","KURE":"KraneShares MSCI All China Health Care Index ETF","BK4139":"生物科技","KCAI":"KraneShares China Alpha Index ETF","BK1583":"高瓴概念","BK0239":"医药制造","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1161":"生物科技","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0828237510.HKD":"SCHRODER ISF BIC (BRAZ IN CH)\"A\" (HKD) ACC","LU0228659784.USD":"施罗德金砖四国基金","ONC":"百济神州","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK1500":"做空集合股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","BK1588":"回港中概股","06160":"百济神州","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"BeOne Medicines 股价开盘上涨近 4%，该公司公布了多个实体瘤项目的临床数据，并制定了明确的未来发展计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"KCAI":1,"ONC":1,"VXUS":1,"06160":1,"KURE":1},"content_text":"BeOne Medicines (06160) opened nearly 4% higher. As of press time, the stock was up 3.73%, trading at HK$228.2, with a turnover of HK$36.279 million.On the news front, BeOne Medicines announced key progress across multiple solid tumour pipeline programs at the 2026 ESMO Congress: its GPC3/4-1BB bispecific antibody for advanced liver cancer achieved an ORR of 36% in Phase I trials with an excellent safety profile; its PRMT5 inhibitor demonstrated an ORR of 38.5% in EGFR wild-type lung cancer, with an intracranial response rate of 30.8%; and its CEA ADC achieved an ORR of as high as 56% in patients with high CEA expression in lung cancer.The company plans to initiate a global registrational clinical trial for later-line liver cancer before the end of 2026, while the PRMT5 inhibitor and CEA ADC are expected to advance to later-stage development in 2027.CICC released a research report stating that BeOne Medicines has made the latest progress in its solid tumour pipeline. The firm maintained its 2026 and 2027 earnings forecasts unchanged and kept its \"Outperform Industry\" rating. Based on a DCF model, the firm maintained its target prices for A-shares, H-shares, and US-listed shares at RMB 340, HK$266, and US$445, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121491466","isCrawlerRequest":true}